Rocket Pharmaceuticals, Inc. (NASDAQ:RCKTW) Short Interest Update

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKTW) was the target of a significant increase in short interest in February. As of February 13th, there was short interest totaling 1,579 shares, an increase of 303.8% from the January 29th total of 391 shares. Based on an average trading volume of 2,424 shares, the short-interest ratio is presently 0.7 days. Based on an average trading volume of 2,424 shares, the short-interest ratio is presently 0.7 days.

Rocket Pharmaceuticals Stock Performance

Shares of NASDAQ RCKTW opened at $0.03 on Friday. The firm has a fifty day simple moving average of $0.02 and a two-hundred day simple moving average of $0.03. Rocket Pharmaceuticals has a 12 month low of $0.01 and a 12 month high of $0.09.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing and commercializing novel, life-transforming gene therapies for rare pediatric diseases. The company’s research and development activities center on inherited genetic disorders, leveraging both lentiviral and adeno-associated virus (AAV) platforms to deliver corrective genes. Rocket’s lead programs include treatments for conditions such as Fanconi anemia, leukocyte adhesion deficiency-I (LAD-I), Danon disease and mucopolysaccharidosis type IIIA (MPS IIIA), each of which represents a high unmet medical need in the pediatric population.

Founded in 2015, Rocket Pharmaceuticals went public in 2018 and trades on the Nasdaq under the ticker symbol RCKTW.